Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
NICE (TA375 (SMC 81/03))
04/12/2024
Indication
Rheumatoid arthritis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
Solution for injection
Comments
Refer to pathway or local board guidelines for preferred formulation
Link to Advice
Advice Published
26/01/2016